Acinar cell carcinoma of the pancreas: New genetic and treatment insights into a rare malignancy

Oncologist

Volumn 16, Issue 12, 2011, Pages 1714-1720

  Lowery, Maeve A ^a   Klimstra, David S ^a   Shia, Jinru ^a   Yu, Kenneth H ^a   Allen, Peter J ^a   Brennan, Murray F ^a   O'reilly, Eileen M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Acinar; BRCA; Genetics; Pancreas

Indexed keywords

BRCA1 PROTEIN; CAPECITABINE; CETUXIMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; IRINOTECAN; OXALIPLATIN; PACLITAXEL; PROTEIN MSH6; PYROXAMIDE; UNCLASSIFIED DRUG;

ACINAR CELL CARCINOMA; ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG INTERMITTENT THERAPY; FEMALE; GENE MUTATION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MEDICAL RECORD REVIEW; METASTASIS; ONCOGENE; OVERALL SURVIVAL; PANCREAS CARCINOMA; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RECURRENT CANCER; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, ACINAR CELL; DNA-BINDING PROTEINS; FEMALE; GENES, BRCA1; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84855169664     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0231     Document Type: Article

References (24)

1. Abraham SC, Wu TT, Hruban RH et al. Genetic and immunohistochemical analysis of pancreatic acinar cell carcinoma: Frequent allelic loss on chromosome 11p and alterations in the APC/betacatenin pathway. Am J Pathol 2002;160:953-962.
2. Holen KD, Klimstra DS, Hummer A et al. Clinical characteristics and outcomes from an institutional series of acinar cell carcinoma of the pancreas and related tumors. J Clin Oncol 2002;20: 4673-4678.
3. Klimstra DS, Rosai J, Heffess CS. Mixed acinar-endocrine carcinomas of the pancreas. Am J Surg Pathol 1994;18:765-778.
4. Stelow EB, Shaco-Levy R, Bao F et al. Pancreatic acinar cell carcinomas with prominent ductal differentiation: Mixed acinar ductal carcinoma and mixed acinar endocrine ductal carcinoma. Am J Surg Pathol 2010;34:510-518.
5. Klimstra DS, Wenig BM, Adair CF et al. Pancreatoblastoma. A clinicopathologic study and review of the literature. Am J Surg Pathol 1995;19: 1371-1389.
6. Klimstra DS. Nonductal neoplasms of the pancreas. Mod Pathol 2007;20(suppl 1):S94-S112.
7. Abraham SC, Wu TT, Klimstra DS et al. Distinctive molecular genetic alterations in sporadic and familial adenomatous polyposis-associated pancreatoblastomas: Frequent alterations in the APC/beta-catenin pathway and chromosome 11p. Am J Pathol 2001;159:1619-1627.
8. Shimizu Y, Ikeda S, Fujimori M et al. Frequent alterations in the Wnt signaling pathway in colorectal cancer with microsatellite instability. Genes Chromosomes Cancer 2002;33:73-81.
9. Skoulidis F, Cassidy L, Pisupati V et al. Germline Brca2 heterozygosity promotes Kras(G12D)-driven carcinogenesis in a murine model of familial pancreatic cancer. Cancer Cell 2010;18:499-509.
10. García-Romero D, Vanaclocha F. Pancreatic panniculitis. Dermatol Clin 2008;26:465-470, vi.
11. Sun Y, Wasserman PG. Acinar cell carcinoma arising in the stomach: A case report with literature review. Hum Pathol 2004;35:263-265.
12. Chiaravalli AM, Finzi G, BertoliniVet al. Colonic carcinoma with a pancreatic acinar cell differentiation. A case report. Virchows Arch 2009;455: 527-531.
13. Jain D, Eslami-Varzaneh F, Takano AM et al. Composite glandular and endocrine tumors of the stomach with pancreatic acinar differentiation. Am J Surg Pathol 2005;29:1524-1529.
14. Butturini G, Pisano M, Scarpa A et al. Aggressive approach to acinar cell carcinoma of the pancreas: A single-institution experience and a literature review. Langenbecks Arch Surg 2011;396:363-369.
15. Mansfield A, Tafur A, Smithedajkul P et al. Mayo Clinic experience with very rare exocrine pancreatic neoplasms. Pancreas 2010;39:972-975.
16. Matos JM, Schmidt CM, Turrini O et al. Pancreatic acinar cell carcinoma: A multi-institutional study. J Gastroint Surg 2009;13:1495-1502.
17. Hartwig W, Denneberg M, Bergmann F et al. Acinar cell carcinoma of the pancreas: Is resection justified even in limited metastatic disease? Am J Surg 2011;202:23-27.
18. Seth AK, Argani P, CampbellKAet al. Acinar cell carcinoma of the pancreas: An institutional series of resected patients and review of the current literature. J Gastrointest Surg 2008;12:1061-1067.
19. Schmidt CM, Matos J, Bentrem D et al. Acinar cell carcinoma of the pancreas in the United States: Prognostic factors and comparison to ductal adenocarcinoma. J Gastrointest Surg 2008;12: 2078-2086.
20. Wisnoski NC, Townsend CM Jr, Nealon WH et al. 672 patients with acinar cell carcinoma of the pancreas: A population-based comparison to pancreatic adenocarcinoma. Surgery 2008;144:141-148.
21. Kitagami H, Kondo S, Hirano S et al. Acinar cell carcinoma of the pancreas: Clinical analysis of 115 patients from Pancreatic Cancer Registry of Japan Pancreas Society. Pancreas 2007;35:42-46.
22. Klimstra DS, Heffess CS, Oertel JE et al. Acinar cell carcinoma of the pancreas. A clinicopathologic study of 28 cases. Am J Surg Pathol 1992;16: 815-837.
23. Falcone A, Ricci S, Brunetti I et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: The Gruppo Oncologico Nord Ovest. J Clin Oncol 2007;25:1670-1676.
24. Conroy T, Desseigne F, Ychou M et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817-1825.